Global Whole Exome Sequencing Industry

Global Whole Exome Sequencing Industry

  • September 2020 •
  • 146 pages •
  • Report ID: 5799972 •
  • Format: PDF
Global Whole Exome Sequencing Market to Reach $3.5 Billion by 2027

Amid the COVID-19 crisis, the global market for Whole Exome Sequencing estimated at US$1 Billion in the year 2020, is projected to reach a revised size of US$3.5 Billion by 2027, growing at a CAGR of 18.7% over the analysis period 2020-2027. Systems, one of the segments analyzed in the report, is projected to record a 17.5% CAGR and reach US$944.2 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Kits segment is readjusted to a revised 21.1% CAGR for the next 7-year period.

The U.S. Market is Estimated at $310.8 Million, While China is Forecast to Grow at 18.5% CAGR

The Whole Exome Sequencing market in the U.S. is estimated at US$310.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$613.5 Million by the year 2027 trailing a CAGR of 18.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 16.6% and 16% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 13.2% CAGR.

Services Segment to Record 17.8% CAGR

In the global Services segment, USA, Canada, Japan, China and Europe will drive the 17.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$356.7 Million in the year 2020 will reach a projected size of US$1.1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$405.7 Million by the year 2027.We bring years of research experience to this 7th edition of our report. The 146-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,
  • Agilent Technologies, Inc.
  • Ambry Genetics
  • BGI Europe
  • Eurofins Genomics GmbH
  • GENEWIZ, Inc.
  • Illumina, Inc.
  • Macrogen, Inc.
  • Roche Nimblegen, Inc.
  • Sengenics
  • Thermo Fisher Scientific, Inc.